Associate Professor Jason Tye-Din is head of coeliac research
at the Walter and Eliza Hall Institute and a gastroenterologist
at The Royal Melbourne Hospital.
Distinct markers found in the blood of people with coeliac disease could lead to a world-first blood test for diagnosing patients after one small meal of gluten.
The availability of a blood-based diagnostic would be a vast improvement on the current approach which requires people to consume gluten for a number of weeks, and even months, for testing to be accurate.
Published today in Science Advances, the research addresses a longstanding mystery about what drives the adverse reaction to gluten in coeliac disease patients.
The peer-reviewed study included the world's top coeliac disease experts from the Walter and Eliza Hall Institute of Medical Research in Australia, University of Oslo in Norway, and in the U.S., Massachusetts General Hospital and University of Chicago. The study was led by Boston-based biotechnology company ImmusanT Inc.
At a glance
Distinct markers in the blood of people with coeliac disease have been identified by an international study.
The findings could lead to the development of a blood-based diagnostic which could offer a diagnosis following one small meal of gluten.
The potential new approach would be a vast improvement on current methods which involve weeks of gluten exposure and an invasive procedure to sample the small intestine.
Associate Professor Jason Tye-Din, head of coeliac research at the Institute and a gastroenterologist at The Royal Melbourne Hospital said work was now underway to explore the development of a simple blood test for coeliac disease.
“For the many people following a gluten-free diet without a formal diagnosis of coeliac disease, all that might be required is a blood test before, and four hours after, a small meal of gluten.
“This would be a dramatic improvement on the current approach, which requires people to actively consume gluten for at least several weeks before undergoing an invasive procedure to sample the small intestine,” Associate Professor Tye-Din said.
Detection in a matter of hours
Coeliac disease affects approximately 1.4 per cent of people globally, many of whom remain undiagnosed. Symptoms of the disease are caused by a damaging immune response to gluten. After consuming gluten, patients can experience reactions such as nausea, vomiting, abdominal pain and diarrhoea.
Dr Bob Anderson, a joint senior author of the paper and the Chief Scientific Officer of ImmusanT Inc., said the new findings could address an important medical need.
“For the first time we have described the inflammatory reaction that patients with coeliac disease experience in the immediate hours after they are exposed to gluten.
“The unpleasant symptoms associated with the disease are linked to an increase in inflammatory molecules in the bloodstream, such as interleukin-2 (IL-2), produced by T cells of the immune system. This response is similar to what happens when an infection is present, however for people with coeliac disease, gluten is the trigger.
“This information underpins a potential new approach to diagnosis that addresses the emerging medical need to identify patients without coeliac disease who may be better served by other treatments for their chronic symptoms,” Dr Anderson said.
Researchers at ImmusanT first discovered the immune markers while assessing blood samples during the Phase 1 trial of a potential coeliac therapy called Nexvax2. Gastrointestinal symptoms in patients injected with the gluten peptides, particularly nausea and vomiting, correlated with higher levels of IL-2 in their blood.
Subsequent testing showed the consumption of gluten produced the same IL-2 response in people with coeliac disease.
Welcome news for coeliac community
CEO of Coeliac Australia, Ms Michelle Laforest, said the finding would be welcome news for the coeliac community in Australia.
“The potential for a one-off gluten challenge and blood test could make a significant difference to many thousands of Australians who report sensitivity to gluten but have been unable to tolerate the current testing approach.
“It is clear this research has the potential to revolutionise the current testing regime for coeliac disease globally,” Ms Laforest said.
The research was supported by the University of Oslo KG Jebsen Coeliac Disease Research Centre, The University of Chicago Celiac Disease Center, the University of Melbourne and ImmusanT Inc.
